East Hills, N.Y. (July 24, 2008) – A new specialized membrane for one-step separation of plasma from whole blood without the use of centrifugation will be introduced by Pall Life Sciences later this month at the annual meeting of the American Association for Clinical Chemistry (AACC). Pall Life Sciences is a business of Pall Corporation (NYSE: PLL).
The Pall VividTM Plasma Separation membrane is a patented membrane in which a highly asymmetric structure is specifically engineered for the generation of plasma from whole blood. The membrane’s properties permit the cellular components of blood – red cells, white cells and platelets – to become captured in the larger pores without lysis. The plasma flows into the smaller pores on the downstream side of the membrane. It can be drawn out of the membrane by capillary action. Rapid separation yields plasma similar in HPLC and 2DE profiles to traditional centrifuged plasma that can be used in downstream diagnostic analysis.
The Pall Vivid Plasma Separation membrane is available in three grades for different starting whole blood requirements and additional chemistries used by the assay developer. Fast separation occurs in less than two minutes. Plasma yield is high, greater than or equal to 80 percent depending on grade. The membrane also has low hemolysis and low non-specific binding of diagnostic biomarkers such as Troponin I.
“Integral to molecular diagnostic operations is the generation of high quality plasma from whole blood samples,” said Kara Cannon, vice president, Pall Life Sciences. “We developed this optimized membrane for diagnostic customers who have told us that they prefer to integrate plasma separation into the test strip or device without relying on centrifuged plasma.”
The Pall Vivid Plasma Separation membrane will be demonstrated at AACC, booth #1752, July 29-31.
At AACC, the company also will introduce the Pall VividTM 170 Lateral Flow Nitrocellulose membrane for assays that require highly consistent measurements for wicking rate and thickness. Variations in both can have detrimental effects to assay sensitivity, reproducibility and reagent consumption. The Pall membrane features tightly controlled Coefficients of Variation (CV’s) for these critical membrane performance parameters.
The membrane results in bright crisp capture lines with low background levels to help reduce the incidence of false positives/negatives. It has consistent levels of protein binding to ensure that the membrane will not non-specifically bind the target analyte as it maintains assay sensitivity levels. A clear polyester backing adds support and rigidity without the use of adhesives that can leach and impede performance of the assay.
Pall offers a wide selection of filtration, separation, and purification materials to help optimize product performance. To order, or for more information about Pall Life Sciences membrane and separation products, contact Pall’s Technical Service Department: 600 South Wagner Road, Ann Arbor, Michigan, 48103; call 800-521-1520 in the U.S. and Canada, or (+) 800-PALL-LIFE outside the U.S. and Canada. Visit Pall Life Sciences at http://www.pall.com/lab or e-mail LabCustomerSupport@pall.com .
Additional Pall Activities at AACC
Poster: Highly Consistent Vivid Lateral Flow Nitrocellulose Membrane and a Simple Quantification Set-Up for the POC Influenza A Immunoassay
Session: 16/Point-of-Care Testing
Thursday, July 31, 2008, 9:30 a.m.
Poster: Novel Filtration System for Separation, Collection, Storage and Processing of Plasma from Cinical Samples
Session: 17/Technology/Design Development
Thursday, July 31, 2008, 9:30 a.m.
OEM Lecture Series: Pall Vivid Nitrocellulose Membrane and Lateral Flow Assay Criticals to Quality
Location: Washington Convention Center, Room 158AB
Date: Tuesday, July 29, 2008, 9:30 a.m.
Industry Workshop: Optimizing Diagnostic Assay Development: Material Considerations for Optimal Performance
Location: Grand Hyatt Washington DC, Room Constitution D
Tuesday, July 29, 2008, 6 p.m.
Data for Pall posters and workshops were generated by Dr. Galina Fomovska, who has been working with membranes and separation materials in the field of diagnostics since 1995. She has expertise in the biomodification of membranes for the selective isolation of cell populations. Dr. Fomovska has four patents issued in the areas of sample collection, archiving and nucleic acid detection. She has a Ph.D. in biochemistry with a concentration in immunochemistry.
About Pall Corporation
Pall Corporation is the global leader in the rapidly growing field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2007 were $2.2 billion. The Company is headquartered in East Hills, New York, with extensive operations around the world. For more information, visit Pall at http://www.pall.com/